Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Deals Drug

Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC

Fineline Cube Jun 2, 2023

China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...

Company Deals

Shenzhen Abrobo Medical Robot Secures RMB 100 Million in Series A Financing for Robotic Development

Fineline Cube Jun 2, 2023

Shenzhen Abrobo Medical Robot Co, Ltd has reportedly raised RMB 100 million via a Series...

Company Drug

Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA

Fineline Cube Jun 2, 2023

China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Eikon Therapeutics Inks Licensing Deals and Raises Funds for Drug Pipeline Expansion

Fineline Cube Jun 2, 2023

US biotech company Eikon Therapeutics has announced three in-licensing deals this week, one of which...

Company Deals

Sino Biopharmaceutical’s Subsidiary invoX Completes Additional Investment in pHion Therapeutics

Fineline Cube Jun 2, 2023

The UK-based invoX Pharma Ltd, a wholly-owned subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177),...

Company Deals

Ucello Therapeutics Secures RMB 150 Million in Series A+ Financing for CAR-T Cell Therapy

Fineline Cube Jun 2, 2023

Ucello Therapeutics, a developer of allogeneic universal chimeric antigen receptor (CAR)-T cell therapies based in...

Company Deals

Eversana Forms Strategic Alliance with China Resource Pharmaceutical for Healthcare Expansion

Fineline Cube Jun 2, 2023

US-based commercial services provider Eversana has announced a strategic alliance with China Resource Pharmaceutical Commercial...

Company Deals

Adcendo ApS Expands Partnership with Duality Biologics for Two Additional ADCs

Fineline Cube Jun 2, 2023

Denmark-based Adcendo ApS has announced the expansion and exercise of options to two additional antibody...

Policy / Regulatory

State Council Mandates Enhanced Oversight of Medical Insurance Funds Utilization

Fineline Cube Jun 1, 2023

The State Council has issued the “Implementation Opinions on Strengthening the Normalization Supervision of the...

Policy / Regulatory

NMPA Issues Procedures for Enhancing Children’s Medication Information in Drug Inserts

Fineline Cube Jun 1, 2023

The National Medical Products Administration (NMPA) has released the “Procedures for Adding Children’s Medication Information...

Company Drug

Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals

Fineline Cube Jun 1, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...

Company Drug

Brii Biosciences Initiates Phase I Study for BRII-297 in Australia

Fineline Cube Jun 1, 2023

China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...

Company Drug

AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial

Fineline Cube Jun 1, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...

Policy / Regulatory

National Health Commission Unveils Action Plan for Medical Quality Improvement (2023-2025)

Fineline Cube Jun 1, 2023

The National Health Commission (NHC) has released the “Action Plan for Comprehensive Improvement of Medical...

Company Policy / Regulatory

Coherus and Junshi Biosciences Await FDA Decision on Toripalimab After Inspection

Fineline Cube Jun 1, 2023

US-based Coherus Biosciences Inc., (NASDAQ: CHRS) has disclosed that the US FDA has recently completed...

Company Drug

Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC

Fineline Cube Jun 1, 2023

China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...

Company Drug

Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM

Fineline Cube Jun 1, 2023

China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...

Company Deals

Amoytop Biotech and Fosun Pharmaceutical Ink Licensing Deal for Pegfilgrastim in China

Fineline Cube Jun 1, 2023

Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced a licensing agreement with Shanghai Fosun...

Company Drug

HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting

Fineline Cube Jun 1, 2023

Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...

Company Drug

Luzhu Biotechnology’s Herpes Zoster Vaccine LZ901 Concludes Phase II Study

Fineline Cube May 31, 2023

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading maker of human vaccines and therapeutic...

Posts pagination

1 … 562 563 564 … 709

Recent updates

  • AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients
  • Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA
  • Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China
  • Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors
  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

AstraZeneca Launches Tezspire in China, Bringing First‑In‑Class TSLP Inhibitor Tezepelumab to Severe Asthma and CRSwNP Patients

Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Company Drug

Fosun Pharma Launches Phase 2 Trial of FXS7553 DPP‑1 Inhibitor for COPD in China

Company Drug

Asieris Pharmaceuticals Wins FDA Clearance for APL‑2501, an Anti‑CLDN6/9 ADC in Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.